Extended Data Fig. 3: Validation of NSC and neuronal marker expression in differentiated CAG17/48 hESCs.
From: Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington’s disease
a,d, Immunofluorescence staining of (a) PAX6 (red) and NESTIN (green) expression in NSCs differentiated from GENEA020 ESCs and (d) βIII-TUBULIN expression (red) in differentiated neurons (DAPI, blue). Similar results were replicated in three independent experiments. Scale bar, 20 μM. b,c, Normalized transcript levels for a panel of (b) pluripotency markers (OCT4, NANOG and REX1) and (c) NSC markers (PAX6, SOX1 and NES) in ESCs and differentiated NSCs. e,f, Normalized transcript levels for a panel of (e) NSC markers (PAX6, SOX1 and NES) and (f) neuronal markers (MAP2, GAD1 and FOXG1) in differentiated NSCs and neurons. Expression levels were normalized to GAPDH and scaled to the expression of (b) ESCs, (c,e) NSCs or (f) neurons. ESCs, n = 2 differentiated lots; NSCs, n = 2 differentiated lots; neurons, n = 4 differentiated lots; mean ± s.d.
